Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 3039-3044

  Sugaya, Masakazu ^a   Uramoto, Hidetaka ^a   Uchiyama, Akihiko ^b   Nagashima, Akira ^c   Nakanishi, Ryoichi ^d   Sakata, Hisanobu ^e   Nakanishi, Kozo ^f   Hanagiri, Takeshi ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^c KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^d Shin Kokura Hospital   (Japan)

^e STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^f ASO IIZUKA HOSPITAL   (Japan)

Author keywords

Adjuvant chemotherapy; Carboplatin; NSCLC; Paclitaxel; Surgical resection; Treatment compliance

Indexed keywords

CARBOPLATIN; CHLORPHENIRAMINE MALEATE; DEXAMETHASONE; PACLITAXEL; RANITIDINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BRONCHITIS; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLITIS; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77955786290     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Minna JD, Roth JA and Gazdor AF: Focus on lung cancer. Cancer Cell 1: 49-52, 2002.
2. Al-Kattan K, Sepsas E, Fountain SW and Townsend ER: Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg 12: 380-384, 1997. (Pubitemid 27397975)
3. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D and Le Chevalier T: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-3559, 2008.
4. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T and Shepherd F; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators: Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352: 2589-2597, 2005.
5. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M and Hurteloup P: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): randomized controlled trial. Lancet Oncol 7: 719-727, 2006.
6. Scagliotti GV, Fossati R, Torri V, Crinò L, Crinò L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F and Tonato M; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IHA non-small cell Lung cancer. J Natl Cancer Inst 95: 1453-1461, 2003.
7. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350: 351-360, 2004.
8. Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, and Green MR: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26: 5043-5051, 2008.
9. Sledge GW: Paclitaxel doublets in metastatic breast cancer: ECOG and HOG studies: Semin in Oncol 23: 57-59, 1996.
10. Conner AC, and Mitchell RB: Biweekly carboplatin and paclitaxel for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol #1672, 1997.
11. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111: 1710-1717, 1997. (Pubitemid 27260107)
12. Calvert AH, Newell DR, Gumbrel LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, and Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 17: 1748-1756, 1989.
13. Jellifie RW, and Jelliffe SM: A computer program for estimation of creatine clearance from unstable serum creatine levels, age, sex and weight. Math Biosci 14: 17-24, 1972.
14. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, 2003.
15. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, Gaspar LE, Pass HI, Spigel DR, Strawn JR, Ung YC, and Shepherd FA; Cancer Care Ontario; American Society of Clinical Oncology: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small cell lung cancer guideline. J Clin Oncol 25: 5506-5518, 2007. (Pubitemid 350232227)
16. van Warmerdam LJ, Huizing MT, Giaccone G, Postmus PE, ten Bokkel Huinink WW, van Zandwijk N, Koolen MG, Heimerhorst TJ, van der Vijgh WJ, Veenhof CH and Beijnen JH: Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 24: 97-104, 1997.
17. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB and Gandara DR: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001.
18. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007.
19. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
20. Georgiadis MS, Russell EK, Gazdar AF and Johnson BE: Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res 3: 449-454, 1997.
21. Gilewski T and Norton L: Cytokineticos and breast cancer chemotherapy. In: Harris JR, Lippman ME, Morrow M et al., (eds.). Diseases of Breast. Philadelphia, PA: Lippincott/Raven, pp. 1877-1884, 1996.
22. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U and Parö G: Randomized trial of single-agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 41: 418-424, 2002. (Pubitemid 35222039)
23. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R and Mills GM: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21: 2933-2939, 2003. (Pubitemid 46621844)
24. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH and Niell HB: A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 17: 104-109, 2006.
25. Tsuchiya S, Takei Y, Watanabe S, Hoshino H, Kaira K, Kawamura Y, Koike Y, Saito R, Nomura F and Sakai S: Phase I study of biweekly paclitaxel (P) and carboplatin (C) for elderly or high risk patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: #731, 2002.
26. Ichiki M, Rikimaru T, Gohara R, Oshita Y, Kamimura T, Hoashi S, Koga T and Aizawa H: A phase I study of biweekly schedule of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: #2752, 2002.
27. Takayama K, Ichiki M, Kawasaki M, Ninomiya K, Miyazaki N, Kuba M, Iwami F and Nakanishi Y: Biweekly combination chemotherapy with paclitaxel and carboplatin for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 7335: #7335, 2004.
28. Yamashita Y, Kataoka K, Ishida T, Matsuura M, Seno N, Mukaida H, Miyahara E, Miyata Y, Okita R, Shimizu K, Watari M, Okumichi T and Okada M: A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer. J Thorac Oncol 3: 61206, 2008.
29. Maruyama R, Yoshino I, Tokunaga S, Ohta M, Kato M, Yoshimine H, Yamazaki K, Nakanishi Y and Ichinose Y: Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501. Gen Thorac Cardiovasc Surg 56: 68-73, 2008.
30. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M and Mack PC: Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 27: 3540-3546, 2009.
31. Uramoto H, Kagami S, Iwashige A and Tsukada J: Evaluation of the quality of life between inpatients and outpatients receiving cancer chemotherapy in Japan. Anticancer Res 27: 1127-1132, 2007. (Pubitemid 46587029)